Leicester – Confidence in Concept 2019
Lead Research Organisation:
University of Leicester
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Organisations
- University of Leicester (Lead Research Organisation)
- Orion Corporation (Collaboration)
- Renfrew Group International (Collaboration)
- LOUGHBOROUGH UNIVERSITY (Collaboration)
- Heidelberg Engineering GmbH (Collaboration)
- Waters Corporation (Collaboration)
- Baylor College of Medicine (Collaboration)
- Isogenica (Collaboration)
- Oxford Nanopore Technologies (Collaboration)
- University Hospitals of Leicester NHS Trust (Collaboration)
- Defence Science & Technology Laboratory (DSTL) (Collaboration)
- Thermo Fisher Scientific (Collaboration)
- University of Southern California (Collaboration)
- University of Washington (Collaboration)
- University of California, Davis (Collaboration)
- OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- Great Ormond Street Hospital (GOSH) (Collaboration)
- UNIVERSITY OF SALFORD (Collaboration)
- UNIVERSITY COLLEGE LONDON (Collaboration)
- Kenya Medical Research Institute (Collaboration)
- University of Queensland (Collaboration)
- UNIVERSITY OF LIVERPOOL (Collaboration)
- University of Texas Southwestern Medical Center (Collaboration)
- University of Pretoria (Collaboration)
Publications
Rufai SR
(2025)
Optic Nerve Head Morphological Variation in Craniosynostosis: A Cohort Study.
in American journal of ophthalmology
Lee H
(2023)
Retinal Development in Infants and Young Children With Albinism: Evidence for Plasticity in Early Childhood.
in American journal of ophthalmology
Ball JD
(2024)
Arterial blood pressure monitoring in stroke cohorts: the impact of reduced sampling rates to optimise remote patient monitoring.
in Blood pressure monitoring
Mahase E
(2020)
Covid-19: Universities roll out pooled testing of students in bid to keep campuses open.
in BMJ (Clinical research ed.)
Jones PJ
(2023)
Hotspots: Adherence in home foot temperature monitoring interventions for at-risk feet with diabetes-A narrative review.
in Diabetic medicine : a journal of the British Diabetic Association
Barker J
(2024)
Artificial intelligence for ventricular arrhythmia capability using ambulatory electrocardiograms
in European Heart Journal - Digital Health
Rufai SR
(2024)
Improved feasibility of handheld optical coherence tomography in children with craniosynostosis.
in Eye (London, England)
Glenn SM
(2022)
Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis.
in Frontiers in cellular and infection microbiology
Danis D
(2025)
A corpus of GA4GH phenopackets: Case-level phenotyping for genomic diagnostics and discovery.
in HGG advances
| Description | Automation of COVID 19 test processing |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://www.gov.uk/government/publications/covid-19-testing-evaluation-of-the-automated-workcell/aut... |
| Description | Drug licensing |
| Geographic Reach | National |
| Policy Influence Type | Contribution to new or improved professional practice |
| Impact | The Scottish Medical Council has accepted the treatment for use by NHS Scotland as a first-line treatment for adults with mesothelioma. Patients in Scotland with malignant pleural mesothelioma that cannot be removed by surgery will be able to have the treatment on the NHS in Scotland. |
| URL | https://www.mesothelioma.uk.com/new-drug-treatment-approved-for-asbestos-related-cancer-patients-in-... |
| Description | Guidelines |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | To complement the RCOphth guidelines we are publishing a new type of guidance, Concise Practice Points (CPPs), these are much shorter documents focussing on individual elements or a combination of elements of patient care where there is recognized uncertainty and they make recommendations for less frequent and targeted clinical situations. |
| URL | https://www.rcophth.ac.uk/news-views/rcophth-launch-new-concise-practice-points/ |
| Description | HUGO representative |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to new or improved professional practice |
| Impact | Reporting of sequence variation in literature and database. This new clinical standard will be adopted globally. |
| Description | Invite to executive committee |
| Geographic Reach | National |
| Policy Influence Type | Contribution to new or improved professional practice |
| URL | https://www.diabetes.org.uk/guide-to-diabetes/complications/feet/taking-care-of-your-feet#:~:text=Wi... |
| Description | Invite to provide SOA expert opinion |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Role in the Office of the National Data Guardian |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.gov.uk/government/organisations/national-data-guardian |
| Description | UHL validating and launching genomic tissue based testing |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Contribution to new or improved professional practice |
| Description | UK enquiry for use of phage therapy |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://parliamentlive.tv/Event/Index/da1d5d2b-c5f8-49c0-b2c3-74254da49096 |
| Description | A platform for rapid development of entry inhibitors for blocking novel viruses. |
| Amount | £103,155 (GBP) |
| Organisation | Defence Science & Technology Laboratory (DSTL) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 07/2026 |
| Description | AKT2I |
| Amount | £37,986 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Advanced tandem quadrupole mass spectrometer with an automated sample extractor for a multiuser interdisciplinary translational research facility |
| Amount | £321,969 (GBP) |
| Funding ID | MC_PC_ MR/X012565/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2022 |
| End | 03/2023 |
| Description | Developing a Prototype Artificial Intelligence-based Eye Tracker (A-EYE) for the Diagnosis and Monitoring of Eye Movement Disorders |
| Amount | £14,884 (GBP) |
| Organisation | Fight for Sight |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2020 |
| Description | Development of a rapid and facile platform for testing viral escape-resistance of therapeutic antibodies & vaccines & determining escape mutations. |
| Amount | £360,359 (GBP) |
| Funding ID | MR/X009521/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2023 |
| End | 10/2024 |
| Description | ECR interdisciplinary fellowship |
| Amount | £63,000 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Establishing Standardised Care Using Multicentre Collaborative Approaches For Paediatric Eye Diseases |
| Amount | £638,327 (GBP) |
| Organisation | Ulverscroft Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Food Safety Research Network |
| Amount | £60,000 (GBP) |
| Organisation | Quadram Institute Bioscience |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2023 |
| End | 04/2024 |
| Description | Funding for MiST |
| Amount | £68,000 (GBP) |
| Organisation | Asthma + Lung UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2023 |
| End | 12/2024 |
| Description | Funding for maintenance of ISO accreditation for Leicester Molecular Diagnostics |
| Amount | £30,000 (GBP) |
| Organisation | University Hospitals of Leicester NHS Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| Description | Future Leaders Fellowship |
| Amount | £1,300,000 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Genomics DTP |
| Amount | £116,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2023 |
| End | 03/2027 |
| Description | In-kind funding for Leicester Molecular Diagnostics |
| Amount | £44,500 (GBP) |
| Organisation | Thermo Fisher Scientific |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Institute for Precision Health |
| Amount | £27,218 (GBP) |
| Organisation | University of Leicester |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2022 |
| End | 07/2023 |
| Description | Knowledge Exchange, Impact & Proof of Concept Fund, 2022 |
| Amount | £10,000 (GBP) |
| Organisation | University of Leicester |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 07/2022 |
| Description | Liquid Biopsies: The Future Of Cancer Patient Diagnosis And Treatment |
| Amount | £455,000 (GBP) |
| Organisation | Samworth Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2023 |
| Description | MD Anderson placement for bispecifics - MRC transition award |
| Amount | £25,000 (GBP) |
| Organisation | MRC Doctoral Training Program |
| Department | MRC DTP Supplementary Funding |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | MRC Clinical Academic Research Partnership - Liquid biopsy in aggressive T-cell lymphoma |
| Amount | £225,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2021 |
| End | 08/2024 |
| Description | Moving Bacteriophages From Bench To Bladder In Recurrent Urinary Tract Infections' |
| Amount | £209,891 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2025 |
| End | 04/2028 |
| Description | NIHR Clinical Lectureship |
| Amount | £252,608 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2023 |
| End | 07/2026 |
| Description | Rosetrees seedcorn award |
| Amount | £15,000 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Salary support |
| Amount | £52,896 (GBP) |
| Organisation | Phelix Research & Development |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2023 |
| End | 03/2024 |
| Description | Sartorius Octet R8: a fast, sensitive, label free protein analysis platform. Equipment fund |
| Amount | £214,587 (GBP) |
| Funding ID | MR/X012646/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Staff salary for Leicester Molecular Diagnostics |
| Amount | £70,000 (GBP) |
| Organisation | University of Leicester |
| Department | NIHR Biomedical Research Centre |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 03/2025 |
| Description | Streamlining translation of genomics research into improved patient outcomes by ensuring precise flow of data from lab to journal to database. |
| Amount | £54,382 (GBP) |
| Organisation | Manchester Technology Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2024 |
| Description | Ulverscroft foundation funding |
| Amount | £639,062 (GBP) |
| Organisation | Ulverscroft Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2023 |
| Description | University of Leicester Staff and Student Covid-19 screening programme |
| Amount | £450,000 (GBP) |
| Organisation | University of Leicester |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2020 |
| Description | Updating VariantValidator to increase its significance and reach for submission as an ICS in UoA5 in REF29 |
| Amount | £5,000 (GBP) |
| Organisation | University of Leicester |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 03/2025 |
| Description | Variant Validator - seedcorn award |
| Amount | £20,000 (GBP) |
| Organisation | University of Manchester |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Wolfson Foundation Intercalation Award |
| Amount | £5,000 (GBP) |
| Organisation | The Wolfson Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | i4i - Call 24 B, LifeMap-Quality-assurance User-focussed Evaluation of Safety and Tolerability (LifeMap-QUEST): developing LifeMap-Vest and LifeMap-Compute for exercise assessment with optimised digital ECG recording for sudden death risk stratification |
| Amount | £838,165 (GBP) |
| Funding ID | NIHR204553 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2022 |
| Description | iCASE studentship on bispecific T cell enhancers |
| Amount | £150,000 (GBP) |
| Organisation | University of Leicester |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2024 |
| End | 06/2028 |
| Title | Development of LifeMap compute software |
| Description | Development of LifeMap compute software to establish reporting of algorithm |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2024 |
| Provided To Others? | No |
| Impact | this will underpin delivery of LifeMap technology |
| Title | Geospatial anaysis |
| Description | developing geospatial analysis tools to study ultra-deep multiplex immunofluorescence datasets for mesothelioma patients |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2024 |
| Provided To Others? | No |
| Impact | No impacts yet, but will help with prediction of response and prognosis in mesothelioma patients |
| Title | JPS016, a HDAC degrader PROTAC |
| Description | JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC). JPS016 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells. Sold commercially by MedChemExpress LLC |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | This is a new potent class I histone deacetylase (HDAC) degrader that can be used as a research tool to study the effects of HDAC degradation and inhibition in biological assays. |
| URL | https://www.medchemexpress.com/jps016.html |
| Title | New models in AlphaFold |
| Description | Generated new models in Alphafold looking at possible inactive and active conformations of BMX, and novel binding pockets |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2023 |
| Provided To Others? | No |
| Impact | Looking at novel binding pockets which could be targeted more specifically to inhibit BMX activity |
| Title | Purification of BMX domains |
| Description | New methods developed to purify various BMX domains for the first time in E.coli. Fragment testing, of chemicals identified in silico has identified a scaffold which binds to the kinase domain of BMX which will act as a starting point to build out of. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2024 |
| Provided To Others? | No |
| Impact | Have shown in cells that the treatment of cancer with known inhibitors targeting BMX does not induce cell death. However, these molecules can phenocopy the previous genetic data, and sensitise cells to existing chemotherapeutics highlighting a novel treatment strategy to overcome apoptotic resistance. This will allow identification of novel BMX inhibitors. |
| Description | Breath sampler for clinical diagnostics and stratified medicine |
| Organisation | Loughborough University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The research team are able to utilise the knowledge and expertise of clinicians and academics within the EMBER consortium - focused on Mass Spectrometer analysis of volatile compounds found in breath. The research team also provide access to patients and patient samples with a broad range of respiratory conditions. |
| Collaborator Contribution | Renfrew Group International (RGi) are an award winning design consultancy company, who provide specific know-how and expertise for innovative product design. RGi have provided design services, electronics manufacturing and rapid prototyping facilities to enable the production of a novel breath collection system. Loughborough University provide access to Mass Spectrometer expertise and equipment complimentary to the expertise in breath analysis at Leicester. |
| Impact | University of Leicester and Renfrew Group engaged in a series of meetings and staff placements (supported by P2D) to establish the feasibility and potential scope of use for a robust novel breath collection system that would provide the ability to offer disposable (sterile) patient contact surfaces, multi channel collection and applicability to normal clinical practice. University of Loughborough, University of Loughborough and Renfrew Group have now produced 3 prototype devices ready to test in a clinical setting. In the process of the project University of Loughborough have contributed £70,000 in funding to the prototype development The project has also benefited from the placement of one of the academic leads into the iCURE commercialisation training programme (estimated £50,000 in-kind contribution) to promote commercial development of the new collection system. The project is in the process of being 'pitched' to a panel of investors through Innovate UK (March 2021) and Mercia Venture Fund (April 2021). (reviewed March 2021 - updated March 2021) |
| Start Year | 2019 |
| Description | Breath sampler for clinical diagnostics and stratified medicine |
| Organisation | Renfrew Group International |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team are able to utilise the knowledge and expertise of clinicians and academics within the EMBER consortium - focused on Mass Spectrometer analysis of volatile compounds found in breath. The research team also provide access to patients and patient samples with a broad range of respiratory conditions. |
| Collaborator Contribution | Renfrew Group International (RGi) are an award winning design consultancy company, who provide specific know-how and expertise for innovative product design. RGi have provided design services, electronics manufacturing and rapid prototyping facilities to enable the production of a novel breath collection system. Loughborough University provide access to Mass Spectrometer expertise and equipment complimentary to the expertise in breath analysis at Leicester. |
| Impact | University of Leicester and Renfrew Group engaged in a series of meetings and staff placements (supported by P2D) to establish the feasibility and potential scope of use for a robust novel breath collection system that would provide the ability to offer disposable (sterile) patient contact surfaces, multi channel collection and applicability to normal clinical practice. University of Loughborough, University of Loughborough and Renfrew Group have now produced 3 prototype devices ready to test in a clinical setting. In the process of the project University of Loughborough have contributed £70,000 in funding to the prototype development The project has also benefited from the placement of one of the academic leads into the iCURE commercialisation training programme (estimated £50,000 in-kind contribution) to promote commercial development of the new collection system. The project is in the process of being 'pitched' to a panel of investors through Innovate UK (March 2021) and Mercia Venture Fund (April 2021). (reviewed March 2021 - updated March 2021) |
| Start Year | 2019 |
| Description | Cytogenetics partnership |
| Organisation | University Hospitals of Leicester NHS Trust |
| Department | Renal University Hospitals of Leicester |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Supporting Cytogenetics at UHL for the implementation of genomic services in Leicester Hospitals (supported by both organisations via a Memorandum of Understanding and a Joint Working Agreement). Results will also inform discussions with the regions Genomic Laboratory Hub around the application of ctDNA testing. |
| Collaborator Contribution | Brought in to cytogenetics ISO accreditation for delivery of diagnostic cancer services via University of Leicester |
| Impact | Delivery of ctDNA profiling for patient stratification to clinical trials |
| Start Year | 2022 |
| Description | Defence Science and Technology partnership |
| Organisation | Defence Science & Technology Laboratory (DSTL) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Building on COVID ligand trap research for applicability to other viral threats |
| Collaborator Contribution | Funding of PhD studentship |
| Impact | PhD studentship investigating 'A platform for rapid development of entry inhibitors for blocking novel viruses' |
| Start Year | 2023 |
| Description | Development of novel antimicrobial agents to target Mycobacterium tuberculosis persisters |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Exploring systems biology in TB |
| Collaborator Contribution | Exploring systems biology in TB |
| Impact | NA |
| Start Year | 2022 |
| Description | Diabetic foot monitoring review |
| Organisation | University of Texas Southwestern Medical Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Joint academic collaboration |
| Collaborator Contribution | Joint academic collaboration |
| Impact | Jones P, Lavery L, Davies MJ, Webb D, Rowlands AV, Hotspots: Adherence in home foot temperature monitoring interventions for at-risk feet with diabetes-A narrative review. Diabetic Medicine 2023; e15189. https://doi.org/10.1111/dme.15189 |
| Start Year | 2023 |
| Description | Diabetic foot ulcers |
| Organisation | University of Southern California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collaboration on forthcoming paper on diabetic foot ulcer prevention |
| Collaborator Contribution | Collaboration on forthcoming paper on diabetic foot ulcer prevention |
| Impact | No outcomes yet |
| Start Year | 2023 |
| Description | Diagnosis of Covid-19 by MS |
| Organisation | Waters Corporation |
| Department | Waters Corporation |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | My research group has developed high fidelity MS proteomics techniques applicable to detection of low concentrations of specific peptides. |
| Collaborator Contribution | Waters created a set of research reagents for the generation of peptides from Covid-19 virus particles and an enrichment capture system to enable MS detection of the virus specific peptides. Waters provided access to these research tools free of charge for my research group to evaluate in clinical samples. |
| Impact | Preliminary results show that MS can detect Covid-19 particles in spiked samples, swab samples and in blood. There is a publication in draft at the moment. (Reviewed March 2021 - Updated March 2021) |
| Start Year | 2020 |
| Description | Face mask |
| Organisation | Kenya Medical Research Institute |
| Country | Kenya |
| Sector | Public |
| PI Contribution | Clinical/academic and technical knowhow plus provision of face mask device |
| Collaborator Contribution | Access to patient populations |
| Impact | None yet |
| Start Year | 2024 |
| Description | Face mask |
| Organisation | University of Pretoria |
| Country | South Africa |
| Sector | Academic/University |
| PI Contribution | Provision of academic and technical knowhow, and face mask colllection device |
| Collaborator Contribution | Access to patient population |
| Impact | Sample analysis underway |
| Start Year | 2021 |
| Description | Face mask |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Clinical/academic knowhow |
| Collaborator Contribution | Clinical/academic knowhow |
| Impact | New partnership |
| Start Year | 2023 |
| Description | Footware fit |
| Organisation | University of Salford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaborator on in-shoe pressure monitoring for the 'footwear fit' study conducted at UoL |
| Collaborator Contribution | Collaborator on in-shoe pressure monitoring for the 'footwear fit' study |
| Impact | Study is currently recruiting patients - 19 recruited, with 9 completed study |
| Start Year | 2023 |
| Description | Genexus sequencing partnership |
| Organisation | Thermo Fisher Scientific |
| Country | United States |
| Sector | Private |
| PI Contribution | Leicester Molecular Diagnostics is now ISO 15189:2012 accredited to deliver sequencing for cancer patients via Cytogenetics. |
| Collaborator Contribution | Provision of 2 x Genexus sequencers |
| Impact | Societal benefit, delivering patient stratification for cancer therapy |
| Start Year | 2022 |
| Description | Isogenica collaboration |
| Organisation | Isogenica |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Clinical input in haematological malignancies |
| Collaborator Contribution | Bispecific antibody development/knowledge exchange |
| Impact | To be developed |
| Start Year | 2022 |
| Description | LifeMap i4i |
| Organisation | Renfrew Group International |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Design and testing of LifeMap |
| Collaborator Contribution | Renfrew Group - we are collaborating with the design company (Renfrew group) on the MRC DPFS project to design a work package with focus to develop a garment that incorporates these shorter standard ECG cables aimed at minimising the noise and improved signal by optimising cable- electrode contact. Renfrew Group is currently supporting the following on NIHR i4i project. |
| Impact | NIHR i4i - NIHR i4i "LifeMap - Quality-assurance User-focussed Evaluation of Safety and Tolerability (LifeMap-QUEST) : developing LifeMap-Vest and LifeMap-Compute for exercise assessment with optimised digital ECG recording for sudden death risk stratification" awarded £840k started |
| Start Year | 2023 |
| Description | Mesothelioma OMICS |
| Organisation | University of Queensland |
| Department | Queensland Institute of Medical Research |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Provision of clinical expertise, access to patient samples |
| Collaborator Contribution | Under discussions for sample analysis |
| Impact | Non yet. Collaboration is with the clinical 0-mx laboratory |
| Start Year | 2023 |
| Description | Multi OMICs in respiratory disease |
| Organisation | Orion Corporation |
| Department | ORION Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Access to EXCEED cohort samples and academic lead for MS analysis |
| Collaborator Contribution | Data lead on analysis |
| Impact | Further funding for 1 year |
| Start Year | 2023 |
| Description | Oxford Nanopore Technologies |
| Organisation | Oxford Nanopore Technologies |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Research team has brought new research application to the ONT portfolio |
| Collaborator Contribution | Advice on data analysis, training |
| Impact | No outputs yet |
| Start Year | 2022 |
| Description | Phage therapy for UTIs |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | A newly established collaboration with the centre for Urological Biology for Knowledge exchange |
| Collaborator Contribution | A newly established collaboration with the centre for phage biology for Knowledge exchange |
| Impact | NA |
| Start Year | 2023 |
| Description | Vision sciences |
| Organisation | Baylor College of Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | New clinical/academic partnership |
| Collaborator Contribution | New clinical/academic partnership |
| Impact | New partnership. No outcomes yet |
| Start Year | 2023 |
| Description | Vision sciences |
| Organisation | Great Ormond Street Hospital (GOSH) |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Clinical/academic contributions |
| Collaborator Contribution | Clinical/academic contributions |
| Impact | New partnership |
| Start Year | 2024 |
| Description | Vision sciences |
| Organisation | Heidelberg Engineering GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Clinical/academic input into opthalmic devices |
| Collaborator Contribution | Engineering knowhow/expertise |
| Impact | New partnership |
| Start Year | 2023 |
| Description | Vision sciences |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Clinical/academic input |
| Collaborator Contribution | Clinical/academic input |
| Impact | New partnership |
| Start Year | 2024 |
| Description | Vision sciences |
| Organisation | University of California, Davis |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | New clinical/academic partnership |
| Collaborator Contribution | New clinical/academic partnership |
| Impact | None yet |
| Start Year | 2023 |
| Description | the optimisation of shallow whole genome sequencing (s-WGS) |
| Organisation | Thermo Fisher Scientific |
| Country | United States |
| Sector | Private |
| PI Contribution | The expertise with the ctDNA workflow has contributed to an MTA being signed between the University and Thermo Fisher for the optimisation of shallow whole genome sequencing (s-WGS), currently used in reproductive health, as a potential low-cost cancer screening tool and/or monitoring tool. |
| Collaborator Contribution | ThermoFisher will provide the software updates and reagents in amounts sufficient to achieve the Purpose |
| Impact | Optimising a low cost cancer screening/monitoring tool |
| Start Year | 2022 |
| Title | METHOD AND APPARATUS FOR EVALUATING CARDIAC FUNCTION |
| Description | The present invention relates to a method for assessing the electrical function of a heart, comprising the steps of:- (1) for each of a plurality of leads of an ECG, determining a value derived from the output of that lead and which corresponds to an action potential duration; (2) for each of the plurality of leads of the ECG, determining a value derived from the output of that lead and which corresponds to a diastolic interval; (3) for each of the plurality of leads of the ECG, determining a relationship between the determined values for action potential duration and for diastolic interval; (3) assessing the differences between the determined relationships for each of the plurality of leads. The invention further relates to apparatus and a computer program that may be used in the method. |
| IP Reference | WO2011117608 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2011 |
| Licensed | No |
| Title | Method for diagnosing dementia or determining the risk of developing dementia |
| Description | The present invention provides novel biomarkers for dementia. Methods for diagnosing dementia or the risk of developing dementia, or for monitoring dementia progression are also provided. The invention also provides methods for determining the therapeutic effect of appropriate treatment regimens or determining a subject's compliance or adherence with a prescribed treatment regimen. A method for monitoring changes in cognition in a subject having or suspected of having dementia is also provided. Corresponding kits, assay devices and uses are also provided. |
| IP Reference | GB2591941 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | none yet. Patent has been renewed in 2023 |
| Title | CONFIRM |
| Description | No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab, an anti-PD-1 antibody, in these patients |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2022 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| UKCRN/ISCTN Identifier | NCT03063450. |
| Impact | The UK has the highest incidence of mesothelioma. The incidence has risen by 497% since the late 1970's and is increasing worldwide due to continued mining and use of asbestos. For patients with mesothelioma who have relapsed after taking pemetrexed and cisplatin, there is currently no standard treatment, making this an urgent unmet need. Recent trials in this area have not found an effective treatment that improves overall survival. Following a debate in the House of Lords, a national survey assessing the research priorities in mesothelioma found that 'exploiting the potential of immunotherapy' was a top priority. This trial was designed in response to that survey. It uses the immunotherapy agent nivolumab which blocks programmed cell death 1 (PD-1) receptor on activated T-cells (a type of white blood cell forming part of the immune system). Early research has found a dependency of mesothelioma on the PD-1 checkpoint. By attaching to PD-1, nivolumab blocks its action (checkpoint inhibition), preventing it from turning off the T-cell, and therefore allowing the immune system to work. PD-1 checkpoint inhibition has revolutionised the treatment of melanoma and it is hoped to be as effective in mesothelioma. This trial is a randomised, double blind placebo controlled trial of patients with mesothelioma who are second or third relapse following a platinum based chemotherapy treatment. Patients will be randomised in a 2:1 ratio (nivolumab: placebo). 336 patients will be recruited from 25 UK centres with the last patient having a minimum of 6 months follow up. |
| URL | https://www.mesothelioma.uk.com/nivolumab-treatment-cleared-for-off-label-use-with-mesothelioma-pati... |
| Title | Footware fit study |
| Description | Evaluation of Footwear Fit Guidelines Under Pressure in At-Risk Feet |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2023 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| UKCRN/ISCTN Identifier | IRAS 273255 |
| Impact | no impacts yet |
| Title | Minimal Residual Disease: A trial using liquid biopsies in solid malignancies. |
| Description | To cross-validate the Thermofisher Oncomine tissue and cfTNA assays (in house) against the FDA approved Foundation Medicine platform by comparison of the spectrum and variant frequency of cancer-specific alterations detected in matched tissue and blood. |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2022 |
| Development Status | Under active development/distribution |
| Impact | Future utility investigated within patient pathway. Trial has just finished recruiting, and awaiting outputs |
| Title | Variant validator |
| Description | A new tool has been developed that builds on the LD3 money. It is currently being updated based on feedback from the HUGO Reposting of Sequence Variants Committee. The software is a stand-alone version of the software we will sell as a service to Aries and other EM systems. It is being used to demonstrate the software to beneficiaries so that they can be "plugged in" if they choose to enter a service agreement |
| Type Of Technology | Software |
| Year Produced | 2023 |
| Impact | Validation of sequence variation for publications |
| URL | https://www607.lamp.le.ac.uk/ |
| Company Name | Bioxhale |
| Description | Bioxhale develops a range of medical breath-testing products for diagnostics. |
| Year Established | 2021 |
| Impact | Breath analysis services and products under development. |
| Website | http://bioxhale.com |
| Company Name | VariantValidator |
| Description | VariantValidator develops a tool that validates genetic sequence variations. |
| Year Established | 2024 |
| Impact | Contributions to the ACMG HUGO Technical Standards for Reporting and Sharing of Interpreted Genomic Variation Working Group who are setting global professional standards for reporting of genetic data in biomedical databases, reports and journals |
| Website | https://variantvalidator.org/ |
| Description | Advocacy event |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | 1. Capitol Hill, Washington DC : Meeting with Senators to share research findings and impact. Advocacy for increasing governmental research funding towards research. Requested funding for NIH $49.2B and NEI $896.5M. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Bright Sparks STEM events |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | This collaboration was discussed with students and parents as part of a wider stall showcasing research undertaken within the Cardiovascular Sciences department. |
| Year(s) Of Engagement Activity | 2023,2024 |
| Description | Case study detection of SARS-Covid-2 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Case study available on New England Biolabs website for LAMP for molecular diagnostics and IVD |
| Year(s) Of Engagement Activity | 2021 |
| URL | http://neb.uk.com/support/lamp-for-molecular-and-in-in-vitro-diagnostics |
| Description | Conference - Invited speaker (Antibiotic Research UK conference) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited talk |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.antibioticresearch.org.uk/antibiotic-research-uk-conference-2024-living-with-chronic-and... |
| Description | Conference poster |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation with published abstract - no DOI ARVO Annual Meeting Abstract | June 2023 Identifying Biomarkers for Papilledema and Pseudopapilledema Rishi Sekhri; Helen Kuht; Ian DeSilva; Zhanhan Tu; Esha Prakash; Sohaib R Rufai; Rebecca McLean; Michael Hisaund; Irene Gottlob; Mervyn George Thomas |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.arvo.org/About/who-we-are/ |
| Description | Conference presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | ASCO 2023 - Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma. Published in Journal of Clinical Oncology. Seminal study leading to manuscript currently under revision in Nature Cancer |
| Year(s) Of Engagement Activity | 2023 |
| Description | Conference presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Published conference abstract - no DOI Rufai et al. Recognition of Intracranial Hypertension in Children using Handheld Optical Coherence Tomography: The RIO Diagnostic Accuracy Study. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4404. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://iovs.arvojournals.org/article.aspx?articleid=2788513 |
| Description | Conference presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation at the 19th Manchester Dysmorphology conference, October 2023. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://docs.google.com/presentation/d/1D7-KE0PJzx95FM7LyMUo1fBfHBG3kJ4U/edit#slide=id.p1 |
| Description | Conference presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Royal College of Ophthalmologists Presentation: Recognition of Intracranial Hypertension in Children using Handheld Optical Coherence Tomography: The RIO Study |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.rcophth.ac.uk/ |
| Description | Conference presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Oxford Global Next Gen Omics Conference Oct 2024. VariantValidator: Standardising variant naming in literature to increase diagnostic rates |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://oxfordglobal.com/precision-medicine/events/nextgen-omics-2024/book-now/ |
| Description | Conference presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Nottingham Eye Symposium Presentation: Recognition of Intracranial Hypertension in Children using Handheld Optical Coherence Tomography: The RIO Study |
| Year(s) Of Engagement Activity | 2023 |
| Description | Conference presentation - IMIG |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation at IMIG (International mesothelioma Interest Group) 2023, Lille. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://imig2023.org/ |
| Description | Conference presentation - Royal Society of Chemistry |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Conference presentation to Royal Society of Chemistry Biomaterials Conference. A comparison of alternative cross-linking techniques for PLGA microsphere loaded Collagen Biomaterials |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.lboro.ac.uk/departments/chemistry/events/2024/rsc-biomaterials-chemistry-group-conferenc... |
| Description | Conference presentation - Royal Society of Chemistry (2) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | RSC Biomaterials Chemistry Group Conference, Loughborough 17-19th January 2024. A Biomimetically Inspired Collagen Meniscal Scaffold with Graduated Pore structure |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.lboro.ac.uk/departments/chemistry/events/2024/rsc-biomaterials-chemistry-group-conferenc... |
| Description | Conference presentation - World Biomaterials Congress |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | World Biomaterials Congress 2024, Daegu, South Korea, May 26-31, 2024. A Biomimetically Inspired Collagen Meniscal Scaffold with Graduated Pore structure |
| Year(s) Of Engagement Activity | 2024 |
| Description | Conference presentation - World Biomaterials Congress (2) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | World Biomaterials Congress 2024, Daegu, South Korea, May 26-31, 2024. Fabrication of collagen conduits for coronary artery bypass grafts |
| Year(s) Of Engagement Activity | 2024 |
| Description | Delivered PPI Training toolkit to LifeMap PPI advisors |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | - 7th May 2024: A pilot of a PPI training toolkit developed over the previous few months was delivered to a group of 7 of the LifeMap-QUEST PPI advisors. Feedback was received and the toolkit amended as a result of this pilot session. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Demonstration of the 3D foot scanner to Leicester Partnerships trust |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Demonstrated equipment utility to the podiatry team at the Leicester Partnerships Trust assessing interest in making test orthotics based on 3D foot scans. This may have significant impact for patient care of those with diabetic foot ulcers. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Dimethyl fumarate eliminates "invisible" Mycobacterium tuberculosis persisters from infected murine organs. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of findings (poster, abstract) at https://www.tuberculosis2022.conferences-pasteur.org/ S. Glenn, O. Turapov, V. Makarov, D. Kell, G. Mukamolova*.Dimethyl fumarate eliminates "invisible" Mycobacterium tuberculosis persisters from infected murine organs. EMBO TB WORKSHOP, Institute Pasteur, Paris, 14/09/22. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.tuberculosis2022.conferences-pasteur.org/ |
| Description | Genomic standards talk - youtube. Fiocruz Brazil |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Youtube video in collaboration with international foundation Fiocruz, to Promote health and social development, generate and disseminate scientific and technological knowledge, |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.youtube.com/watch?v=bEAGUsN9Z2I&t=2564s |
| Description | International conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heart Rhythm 2023 (HRS) presentation at New Orleans, LA: PO-05-182 DETERMINING THE PREDICTIVE VALUE OF HOLTER MONITORS FOR SUDDEN CARDIAC DEATH BY ARTIFICIAL INTELLIGENCE DEEP HOLTER SCD |
| Year(s) Of Engagement Activity | 2023 |
| Description | Interview for national newspaper |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Phage therapy work published in the Guardian |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.theguardian.com/science/2023/mar/03/increase-use-of-phages-to-combat-antibiotic-resistan... |
| Description | Myocardial infarction detection and quantification based on Convolution neural network with error correction. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr Xin Li gave an oral presentation at the IEEE WORLD CONGRESS ON COMPUTATIONAL INTELLIGENCE (WCCI) 2020, 19 - 24th July, 2020, Glasgow (UK), "Myocardial infarction detection and quantification based on Convolution neural network with error correction." |
| Year(s) Of Engagement Activity | 2020 |
| Description | NIH Albinism Genes Variant Curation Expert Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Pi invited to be part of the NIH Albinism Genes Variant Curation Expert Group and work within the ClinGen ocular guidelines group: https://www.clinicalgenome.org/working-groups/clinical-domain/ocular-cdwg/ |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.clinicalgenome.org/working-groups/clinical-domain/ocular-cdwg/ |
| Description | Nystagmus Network Open Day (Cardiff University, 24th June 2022). |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Conducted engagement activities with patients through the nystagmus network community and Global Albinism Alliance committee. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Organisation and attendence of International Scientific Conference on Albinism (ISCA) 2022 - 16-19 November 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Organisation and attendance of International Scientific Conference on Albinism (ISCA) 2022 - 16-19 November 2022. This included providing lay talks to patients and public. |
| Year(s) Of Engagement Activity | 2022 |
| Description | PPI meeting on LifeMap vest |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | - 19th June 2024: PPI meeting to provide an update on the project, the LifeMap-Vest, the PPI training toolkit, patient information and begin discussions about updating the LifeMap website. The group provided feedback on the current website and made suggestions about what the updated website should include. |
| Year(s) Of Engagement Activity | 2024 |
| Description | PPI meeting to discuss the ICTMC conference poster and about making patient information videos in different languages |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | - 4th September 2024: PPI meeting to discuss the ICTMC conference poster and about making patient information videos in different languages. The group advised on the visual aspects and the contents of the poster, such as the methods/findings. They also advised on the contents of the English script that will be translated for the patient information video, and made suggestions about what the video should include. |
| Year(s) Of Engagement Activity | 2024 |
| Description | PPI meeting to present the concept of health economics to the PPI advisory group and how this is done in LifeMap |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | - 12th February 2025: PPI meeting to present the concept of health economics to the PPI advisory group and how this is done in LifeMap, look at an online mock-up of the LifeMap website developed based on the groups previous feedback, and discuss options for the future of the group. Outputs include suggestions on how the group could continue, and to get the group thinking about what things are important to patients that should be included in the health economics analysis. |
| Year(s) Of Engagement Activity | 2024 |
| Description | PPI meeting to provide an update on the LifeMap project |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | - 31st July 2024: PPI meeting to provide an update on the project and discuss ideas for how to make the patient information more inclusive including different languages. The group suggested what other languages besides English that should be included, tools that could be used to support translation and issues/nuances to consider when translating. |
| Year(s) Of Engagement Activity | 2024 |
| Description | PPI workshop for the advisory group to contribute further to the LifeMap website design, |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | - 29th November 2024: PPI workshop for the advisory group to contribute further to the LifeMap website design, discuss patient information for future study proposals including ICD patients, and outline the history, current and future research opportunities for LifeMap. The group created several mock-up versions of the main information for the LifeMap website, and identified important points to consider when creating patient information for research involving people with or being offered ICDs. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Patient group workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Regular patient and public involvement events through our Biomedical Research Centre |
| Year(s) Of Engagement Activity | 2023,2024 |
| Description | Press Release - Researchers identify how multiple genes impact vision development and result in rare sight disorder |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Press release by University of Leicester on the largest study to date involving multiple centres across the world (UK, South Korea, Denmark, Netherlands, USA, China, France, Australia, Germany, Brazil and India) led by team at the University of Leicester. High impact publication in Ophthalmology (IF = 14.27) The international effort led by researchers at the University of Leicester consisted of 20 expert centres , examining the genes associated with arrested development of the fovea. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://le.ac.uk/news/2022/april/fovea-genes |
| Description | School visit |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Bright Sparks STEM event On Saturday June 17th 2023, we organised and ran a stall at the Bright Sparks STEM event at Leicester Grammar School showcasing all the brilliant work done across the entire department to KS2 and KS3 children and parents/carers. We exhibited the Cardiovascular Operation game and guess the MRI fruit and vegetables which were both well received and initiated lots of engaging conversations. We were commended by the event organisers who were keen to have us back at future events! |
| Year(s) Of Engagement Activity | 2023 |
| Description | Sharing of Research findings to donors |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Third sector organisations |
| Results and Impact | 2. Fight for Sight (30/11/23): Sharing research findings on behalf of Fight for Sight to high-level donors to share impact and increase funding donations for vision research. Fight for sight profile: |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.fightforsight.org.uk/news-and-articles/articles/news/meet-the-researcher-dr-mervyn-thoma... |
| Description | Specific PPI meeting with Gujarati/Hindi speaking members of the PPI advisory group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | - 11th December 2024: Specific PPI meeting with Gujarati/Hindi speaking members of the PPI advisory group to review samples of the Gujarati/Hindi audio for the patient information videos. The group provided feedback that was passed onto the translators to improve the patient information in these languages that will be used in the final information videos. |
| Year(s) Of Engagement Activity | 2024 |